FENC FENNEC PHARMACEUTICALS INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1211583 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY71.1%
TTM net income YoY129.2%
TTM EPS YoY111.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin5.6%
Net margin3.1%
FCF margin—
EBITDA margin—
Returns
ROE9.1%
ROA3.1%
ROIC (approx.)—
Asset turnover1.00x
Leverage & solvency
Liabilities / assets41.1%
Debt / equity0.00x
Current ratio6.11x
Interest coverage11.66x
Cash quality & payout
Operating cash flow / net income1.55x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $19.61M | $17.87M | $15.11M | $13.78M | $12.46M | $9.65M | $8.75M | $7.92M |
| R&D expense | $154,000 | $118,000 | $49,000 | $20,000 | $29,000 | $107,000 | $94,000 | $50,000 |
| SG&A expense | $3.91M | $4.64M | $3.19M | $8.44M | $5.45M | $6.53M | $5.87M | $4.20M |
| Operating income | $4.65M | $1.74M | -$119,000 | -$2.55M | -$189,000 | -$2.73M | -$808,000 | -$934,000 |
| Interest expense | $1,000 | $3,000 | $7,000 | $308,000 | $586,000 | $594,000 | $592,000 | $966,000 |
| Pretax income | $4.97M | $2.02M | — | -$4.68M | -$638,000 | -$3.15M | — | — |
| Income tax | $332,000 | $42,000 | — | $106,000 | $0 | $0 | $0 | — |
| Net income | $4.64M | $1.97M | $201,000 | -$4.79M | -$638,000 | -$3.15M | -$1.17M | -$1.99M |
| EPS (basic) | 0.13 | 0.06 | 0.01 | — | -0.02 | -0.11 | -0.04 | — |
| EPS (diluted) | 0.12 | 0.05 | 0.01 | — | -0.02 | -0.11 | -0.04 | — |
| Weighted avg. shares (diluted) | 38.08M | 36.43M | 35.55M | — | 27.89M | 27.66M | 27.58M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $48.68M | $41.25M | $40.18M | $36.79M | $21.95M | $18.70M | $22.68M | $26.63M |
| Current assets | $80.95M | $72.50M | $66.88M | $67.04M | $46.06M | $40.79M | $42.98M | $44.12M |
| Total assets | $83.54M | $75.75M | $71.82M | $70.55M | $49.26M | $44.88M | $46.40M | $44.95M |
| Current liabilities | $13.24M | $12.39M | $9.59M | $10.52M | $9.81M | $8.41M | $8.37M | $6.92M |
| Long-term debt | — | — | — | — | $19.38M | $19.36M | $19.35M | $19.34M |
| Total debt | — | — | — | — | $19.38M | $19.36M | $19.35M | $19.34M |
| Total liabilities | $34.35M | $33.31M | $34.15M | $35.08M | $53.75M | $52.34M | $52.28M | $50.82M |
| Shareholders' equity | $49.19M | $42.44M | $37.67M | $35.47M | -$4.49M | -$7.46M | -$5.88M | -$5.87M |
| Net debt | — | — | — | — | -$2.57M | $659,000 | -$3.32M | -$7.30M |
| Shares outstanding | 35.22M | 35.03M | 34.54M | 34.16M | 28.06M | 27.73M | 27.59M | 27.53M |
| Cash flow statement | ||||||||
| Operating cash flow | $6.68M | $50,000 | $2.38M | -$5.96M | $1.49M | -$3.69M | -$4.32M | -$1.47M |
| Financing cash flow | $753,000 | $1.02M | $1.01M | $20.80M | $1.75M | -$284,000 | $359,000 | -$12.21M |
| Stock-based compensation | $1.35M | $1.77M | $990,000 | $2.52M | $2.22M | $1.49M | $798,000 | $1.12M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.